Immunology Investor Event

sanofi DupixentⓇ: Potential best-in-disease in Type 2 Asthma DupixentⓇ significantly reduced Asthma attacks and demonstrated rapid and sustained improvements in lung function across a broad population of Type 2 Asthma patients ¹ as young as 6 years ≥18 Progressively declining exacerbation rate years 6-11 Rapid and sustained improvement in lung function5 Unadjusted annualized exacerbation rate across 3 years² (n=182) years FEV1 percent predicted, LS mean A from baseline (n=350) 2.1 Historical³ 0.4 0.3 0.2 Year 1 Year 2 Year 3 >60% Type 2 patients had no exacerbations for 3 years Predicted FEV, in percent 220006 + N 14 12 * Improvement as early as week 2 sustained up to 52 weeks *** ** *** ****** *** ******** ~2X *** *** ** ** DupixentⓇ4 Placebo 0 0 2 4 6 8 10 12 16 20 24 28 32 36 40 44 48 52 Week 1. Type 2 phenotype: Eos ≥150 or FeNo ≥20 ppb, and/or OCS dependence. 2. Population treated with dupilumab 300 mg Q2W across QUEST & TRAVERSE (with 96-week data on TRAVERSE). 3. Historical refers to the mean event count of severe exacerbations in the 1 year prior to QUEST. 4. Dupixent dose: 100mg q2w (16 to ≤ 30kg)/200mg q2w (> 30kg). 5. The overall rates of adverse events were 83% for DupixentⓇ and 80% for placebo 22 Immunology Investor Event

View entire presentation